MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

37.38 -0.53

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

37.14

Max

37.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	11.959 88.032
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+16.52% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	496M 2.2B
Ankstesnė atidarymo kaina	37.91
Ankstesnė uždarymo kaina	37.38

Naujienos nuotaikos

By Acuity

50%

141 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-31 22:20; UTC

Pagrindinės rinkos jėgos

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

2025-12-31 17:31; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

2025-12-31 16:30; UTC

Pagrindinės rinkos jėgos

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

2025-12-31 15:19; UTC

Pagrindinės rinkos jėgos

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

2025-12-31 15:17; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

2025-12-31 14:37; UTC

Pagrindinės rinkos jėgos

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

2026-01-01 23:35; UTC

Rinkos pokalbiai

Gold Rises Amid Geopolitical Risks -- Market Talk

2026-01-01 21:29; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

2026-01-01 21:29; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Sold Stake in JV to Tata Steel

2026-01-01 21:28; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

2026-01-01 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-01 09:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-31 21:13; UTC

Įsigijimai, susijungimai, perėmimai

10 People to Watch in Wealth Management in 2026 -- Barrons.com

2025-12-31 20:40; UTC

Rinkos pokalbiai

Dollar Posting Its Worst Year Since 2017 -- Market Talk

2025-12-31 20:22; UTC

Rinkos pokalbiai

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

2025-12-31 19:50; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

2025-12-31 19:31; UTC

Rinkos pokalbiai

Precious Metals Cap Off Record Runs -- Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-31 18:50; UTC

Rinkos pokalbiai

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

2025-12-31 17:17; UTC

Rinkos pokalbiai

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

2025-12-31 17:16; UTC

Pagrindinės rinkos jėgos

OwlTing Climbs on Launch of $10M Stock-Buyback Program

2025-12-31 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-31 17:00; UTC

Įsigijimai, susijungimai, perėmimai

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

2025-12-31 15:57; UTC

Įsigijimai, susijungimai, perėmimai

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

2025-12-31 15:54; UTC

Rinkos pokalbiai

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

2025-12-31 15:02; UTC

Pagrindinės rinkos jėgos

Nike Shares Rise After CEO Hill Buys $1M of Shares

2025-12-31 14:40; UTC

Įsigijimai, susijungimai, perėmimai

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

2025-12-31 14:20; UTC

Rinkos pokalbiai

Crude Futures On Track to End the Year With Losses -- Market Talk

2025-12-31 13:46; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

16.52% į viršų

12 mėnesių prognozė

Vidutinis 43.6 USD 16.52%

Aukščiausias 55 USD

Žemiausias 32 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

141 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.